

Pavel A Shesternya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1749958/publications.pdf>

Version: 2024-02-01

22
papers

1,972
citations

840776

11
h-index

794594

19
g-index

24
all docs

24
docs citations

24
times ranked

2724
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. <i>Rheumatology</i> , 2021, 60, 2277-2287.	1.9	36
2	The Role of Single-Nucleotide Variants of NOS1, NOS2, and NOS3 Genes in the Comorbidity of Arterial Hypertension and Tension-Type Headache. <i>Molecules</i> , 2021, 26, 1556.	3.8	19
3	Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. <i>Biomedicines</i> , 2021, 9, 451.	3.2	20
4	Magnetic resonance tomography capabilities and limitations in managing the efficacy of treatment with biological disease modifying anti-rheumatic drugs in ankylosing spondylitis. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 29-34.	0.5	1
5	Analysis of safety of bioactive concentrate of small sea fish therapy in comorbid patients with osteoarthritis. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 103-110.	0.5	1
6	Clinical case of Scheuermann-Mau disease – reminiscence of a century-long history. <i>Siberian Medical Review</i> , 2021, 5, 111-116.	0.2	0
7	New Opportunities for Determining the Terms of Carrying out the Control Coronarangiography after Percutaneous Coronary Intervention. <i>Acta Biomedica Scientifica</i> , 2020, 5, 51-59.	0.2	0
8	Strategies and trends for organization of medical and psychological assistance in post-pandemic period. <i>Siberian Medical Review</i> , 2020, , 5-10.	0.2	1
9	Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 27-34.	0.8	15
10	Clinical application of chromosome 9p21.3 genotyping in patients with coronary artery disease. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3100-3108.	1.8	2
11	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019, 58, 2193-2202.	1.9	34
12	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. <i>BioDrugs</i> , 2019, 33, 79-91.	4.6	26
13	OP0232 – NETAKIMAB REDUCES THE DISEASE ACTIVITY OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. RESULTS OF ASTERA STUDY. , 2019, , .		2
14	Angiographic dynamics of coronary flow state after percutaneous coronary intervention in carriers of polymorphic RS1800470 variants of the TGF- β 1 gene. <i>Russian Journal of Cardiology</i> , 2019, , 77-82.	1.4	0
15	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. <i>MAbs</i> , 2018, 10, 934-943.	5.2	43
16	Clinical aspects of the use of etanercept in treatment of rheumatoid arthritis.. <i>Klinicheskaia Meditsina</i> , 2018, 95, 1007-1012.	0.1	0
17	Association of RS1800470 polymorphic variants of the transforming growth factor β 1 (TGF- β 1) gene with the severity of coronary atherosclerosis. <i>Russian Journal of Cardiology</i> , 2018, , 43-47.	1.4	5
18	A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 566-570.	0.9	78

#	ARTICLE	IF	CITATIONS
19	Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. <i>BioDrugs</i> , 2017, 31, 357-367.	4.6	28
20	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. <i>BioDrugs</i> , 2017, 31, 369-377.	4.6	41
21	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 1406-1415.	27.0	1,607
22	Association of ADRB1 Gene Polymorphism with Atrial Fibrillation. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 249-253.	0.7	8